LIFECORE BIOMEDICAL, INC. Payments for Restructuring
LIFECORE BIOMEDICAL, INC. (LFCR) reported Payments for Restructuring of $2.55 million for the 12-month period ending 2025-05-25, per its 10-KT filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. payments for restructuring for the quarter ending 2025-05-25 was $1.29M, a 96.35% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. payments for restructuring for the quarter ending 2025-02-23 was $480.00K, a 95.12% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. payments for restructuring for the quarter ending 2024-11-24 was $346.00K, a 74.54% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. payments for restructuring for the quarter ending 2024-08-25 was $437.00K, a 41.42% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. payments for restructuring for fiscal 2025 was $2.55M, a 15.13% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. payments for restructuring for fiscal 2024 was $3.01M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-05-25 | $1.29M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $1.77M derived: sum of 2 quarters · filed 2026-03-16 | $2.12M derived: sum of 3 quarters · filed 2026-03-16 | $2.55M 10-KT · filed 2026-03-16 |
| 2025-02-23 | $480.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | $826.00K derived: sum of 2 quarters · filed 2025-04-03 | $1.26M 10-Q · filed 2025-04-03 | $1.92M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-11-24 | $346.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | $783.00K 10-Q · filed 2025-01-02 | $1.44M derived: sum of 3 quarters · filed 2026-03-16 | $1.69M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-08-25 | $437.00K 10-Q · filed 2024-10-04 | $1.09M derived: sum of 2 quarters · filed 2026-03-16 | $1.34M derived: sum of 3 quarters · filed 2026-03-16 | $2.70M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-05-26 | $657.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $903.00K derived: sum of 2 quarters · filed 2026-03-16 | $2.26M derived: sum of 3 quarters · filed 2026-03-16 | $3.01M 10-KT · filed 2026-03-16 |
| 2024-02-25 | $246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $1.60M derived: sum of 2 quarters · filed 2024-08-09 | $2.35M 10-Q · filed 2024-08-09 | |
| 2023-11-26 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $2.10M 10-Q · filed 2024-08-09 | ||
| 2023-08-27 | $746.00K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |